CA2865534C - Salts of a dihydroquinazoline derivative - Google Patents
Salts of a dihydroquinazoline derivative Download PDFInfo
- Publication number
- CA2865534C CA2865534C CA2865534A CA2865534A CA2865534C CA 2865534 C CA2865534 C CA 2865534C CA 2865534 A CA2865534 A CA 2865534A CA 2865534 A CA2865534 A CA 2865534A CA 2865534 C CA2865534 C CA 2865534C
- Authority
- CA
- Canada
- Prior art keywords
- salt
- methoxy
- fluoro
- dihydroquinazoline
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(*([C@@]1CC(OC)=O)c2cc(*)ccc2ON)=*c2c1cccc2N Chemical compound CC(*([C@@]1CC(OC)=O)c2cc(*)ccc2ON)=*c2c1cccc2N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012101673A DE102012101673A1 (de) | 2012-02-29 | 2012-02-29 | Salze eines Dihydrochinazolinderivats |
| DE102012101673.9 | 2012-02-29 | ||
| PCT/EP2013/054109 WO2013127968A1 (de) | 2012-02-29 | 2013-02-28 | Besylat- und tosylatsalze eines dihydrochinazolinderivates und ihre verwendung als antivirale mittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2865534A1 CA2865534A1 (en) | 2013-09-06 |
| CA2865534C true CA2865534C (en) | 2019-04-02 |
Family
ID=47884256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2865534A Active CA2865534C (en) | 2012-02-29 | 2013-02-28 | Salts of a dihydroquinazoline derivative |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9512085B2 (pl) |
| EP (1) | EP2820000B1 (pl) |
| JP (1) | JP6235493B2 (pl) |
| CN (1) | CN104144916B (pl) |
| CA (1) | CA2865534C (pl) |
| CY (1) | CY1118284T1 (pl) |
| DE (1) | DE102012101673A1 (pl) |
| DK (1) | DK2820000T3 (pl) |
| ES (1) | ES2583360T3 (pl) |
| HR (1) | HRP20160886T1 (pl) |
| HU (1) | HUE027751T2 (pl) |
| LT (1) | LT2820000T (pl) |
| PL (1) | PL2820000T3 (pl) |
| PT (1) | PT2820000T (pl) |
| RS (1) | RS54989B1 (pl) |
| SI (1) | SI2820000T1 (pl) |
| SM (1) | SMT201600343B (pl) |
| WO (1) | WO2013127968A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2855695B2 (ja) | 1989-09-22 | 1999-02-10 | 東洋紡績株式会社 | 特殊捲縮加工糸 |
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE102012101673A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| DE102012101659A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| RS58882B1 (sr) * | 2013-06-19 | 2019-08-30 | Aicuris Anti Infective Cures Gmbh | Amorfni letermovir i njegove čvrste farmaceutske formulacije za oralno davanje |
| US9890128B2 (en) | 2013-12-12 | 2018-02-13 | Merck Sharp & Dohme Corp. | Process for making substituted quinazoline compounds |
| WO2017091453A1 (en) * | 2015-11-24 | 2017-06-01 | Merck Sharp & Dohme Corp. | Novel processes for making substituted quinazoline compounds using hydrogen bonding catalysts |
| WO2019154192A1 (zh) * | 2018-02-08 | 2019-08-15 | 南京明德新药研发股份有限公司 | 一种3,4-二氢噻吩并[3,2-d]嘧啶类化合物的晶型及其制备方法 |
| IT202000017617A1 (it) | 2020-07-21 | 2022-01-21 | Olon Spa | Procedimento per la preparazione di un intermedio utilizzato nella sintesi del letermovir |
| CA3189271A1 (en) | 2020-08-17 | 2022-02-24 | Girij Pal Singh | A precipitation process for amorphous letermovir |
| CN113880776B (zh) * | 2021-11-16 | 2023-06-16 | 山东诚创蓝海医药科技有限公司 | 一种莱特莫韦中间体的制备方法 |
| CN117229223A (zh) * | 2022-06-08 | 2023-12-15 | 苏州远智医药科技有限公司 | 一种杂环衍生物及其药物组合物、应用 |
| CN119731157A (zh) * | 2022-08-15 | 2025-03-28 | 上海迪赛诺化学制药有限公司 | 一种来特莫韦无定形的制备方法 |
| PY24113872A (es) | 2023-12-21 | 2025-07-29 | Aic 246 Ag & Co Kg | Sales diastereoméricas de aminoalchohol y aminoéter de ácido 2-[(4r,s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il]acético y su uso para separación enantiomérica.- |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (de) * | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE10352499A1 (de) * | 2003-11-11 | 2005-06-09 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline II |
| DE102005027517A1 (de) | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
| DE102011101446A1 (de) | 2011-05-10 | 2012-11-15 | Aicuris Gmbh & Co. Kg | Herstellung von "Dense Bodies" (DB) |
| DE102012101659A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| DE102012101673A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| RS58882B1 (sr) | 2013-06-19 | 2019-08-30 | Aicuris Anti Infective Cures Gmbh | Amorfni letermovir i njegove čvrste farmaceutske formulacije za oralno davanje |
-
2012
- 2012-02-29 DE DE102012101673A patent/DE102012101673A1/de not_active Ceased
-
2013
- 2013-02-28 LT LTEP13709345.6T patent/LT2820000T/lt unknown
- 2013-02-28 SI SI201330242A patent/SI2820000T1/sl unknown
- 2013-02-28 US US14/381,625 patent/US9512085B2/en active Active
- 2013-02-28 EP EP13709345.6A patent/EP2820000B1/de active Active
- 2013-02-28 WO PCT/EP2013/054109 patent/WO2013127968A1/de not_active Ceased
- 2013-02-28 HU HUE13709345A patent/HUE027751T2/en unknown
- 2013-02-28 ES ES13709345.6T patent/ES2583360T3/es active Active
- 2013-02-28 HR HRP20160886TT patent/HRP20160886T1/hr unknown
- 2013-02-28 CN CN201380011791.1A patent/CN104144916B/zh active Active
- 2013-02-28 CA CA2865534A patent/CA2865534C/en active Active
- 2013-02-28 RS RS20160574A patent/RS54989B1/sr unknown
- 2013-02-28 JP JP2014559231A patent/JP6235493B2/ja active Active
- 2013-02-28 PT PT137093456T patent/PT2820000T/pt unknown
- 2013-02-28 DK DK13709345.6T patent/DK2820000T3/en active
- 2013-02-28 PL PL13709345T patent/PL2820000T3/pl unknown
-
2016
- 2016-07-18 CY CY20161100699T patent/CY1118284T1/el unknown
- 2016-09-30 SM SM201600343T patent/SMT201600343B/it unknown
- 2016-10-31 US US15/338,984 patent/US10287254B2/en not_active Ceased
-
2017
- 2017-07-03 US US15/640,661 patent/US20170362186A1/en not_active Abandoned
-
2021
- 2021-05-14 US US17/320,587 patent/USRE49897E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SI2820000T1 (sl) | 2016-08-31 |
| WO2013127968A1 (de) | 2013-09-06 |
| EP2820000A1 (de) | 2015-01-07 |
| CY1118284T1 (el) | 2017-06-28 |
| LT2820000T (lt) | 2016-11-10 |
| DE102012101673A1 (de) | 2013-08-29 |
| PL2820000T3 (pl) | 2017-07-31 |
| USRE49897E1 (en) | 2024-04-02 |
| HK1205511A1 (zh) | 2015-12-18 |
| RS54989B1 (sr) | 2016-11-30 |
| HUE027751T2 (en) | 2016-10-28 |
| JP6235493B2 (ja) | 2017-11-22 |
| CN104144916A (zh) | 2014-11-12 |
| US9512085B2 (en) | 2016-12-06 |
| US20170114026A1 (en) | 2017-04-27 |
| DK2820000T3 (en) | 2016-07-25 |
| ES2583360T3 (es) | 2016-09-20 |
| EP2820000B1 (de) | 2016-04-20 |
| US10287254B2 (en) | 2019-05-14 |
| CA2865534A1 (en) | 2013-09-06 |
| SMT201600343B (pl) | 2016-11-10 |
| JP2015508800A (ja) | 2015-03-23 |
| US20170362186A1 (en) | 2017-12-21 |
| CN104144916B (zh) | 2016-08-24 |
| PT2820000T (pt) | 2016-07-20 |
| HRP20160886T1 (hr) | 2016-09-23 |
| US20150045371A1 (en) | 2015-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE49897E1 (en) | Salts of a dihydroquinazoline derivative | |
| CA2865049C (en) | Salts of a dihydroquinazoline derivative | |
| JP2018508583A (ja) | キナゾリン誘導体の塩およびその製造方法 | |
| US9073899B2 (en) | Solid forms of dabigatran etexilate mesylate and processes for their preparation | |
| EP2269994B1 (en) | The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof | |
| US7709491B2 (en) | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | |
| EP2751094B1 (en) | Novel crystal form | |
| AU2010240717A1 (en) | Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-[1- (N-methylcarbamoylmethyl)-piperidin-4-yl]quinazoline | |
| CN115052855A (zh) | 酰胺化合物的制备方法、其晶型及其盐类 | |
| HK1205511B (en) | Besylate and tosylate salts of a dihydroquinazoline derivative and their use as antiviral agents | |
| WO2025235717A2 (en) | Crystal forms of a parp1 inhibitor and preparation thereof | |
| HK40074212A (en) | Processes for producing amide compounds, and their crystalline and salt form | |
| EP1713769B1 (en) | Amorphous tamsulosin hydrochloride | |
| HK1205509B (en) | Sodium and calcium salts of a dihydroquinazoline derivate and their use as antiviral agents | |
| HK40000352A (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| HK1198534B (en) | Novel crystal form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20161103 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - SMALL Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250204 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250204 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250204 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - SMALL Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251209 |